RenovoRx (RNXT) Liabilities and Shareholders Equity (2020 - 2026)

RenovoRx has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $14.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 12.8% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.9 million (up 1.61% YoY) and the FY2025 annual result came in at $8.1 million, changed 0.28% from the prior year.
• Liabilities and Shareholders Equity improved to $14.0 million in Q1 2026 per RNXT's latest filing, from $8.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $16.0 million in Q1 2025 and troughed at $1.5 million in Q4 2023.
• A 5-year average of $9.1 million and a median of $9.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 79.82% in 2023, then jumped 453.75% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $7.3 million in 2022, then tumbled by 79.82% to $1.5 million in 2023, then surged by 453.75% to $8.1 million in 2024, then declined by 0.28% to $8.1 million in 2025, then soared by 72.5% to $14.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $14.0 million, $8.1 million, and $11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.